IDH3A and glioblastoma: Isocitrate dehydrogenase (IDH) mutations and chromosomal arms 1p and 19q (1p/19q) codeletions favor longer survival of GBM patients and are important molecular biomarkers for GBM diagnosis and treatment [28, 29].